FindMyKOL
Clinical trialNCT04044859Active, not recruitingPhase 1Interventional

ADP-A2M4CD8 as Monotherapy or in Combination With Either Nivolumab or Pembrolizumab in HLA-A2+ Subjects With MAGE-A4 Positive Tumors (SURPASS)

NCT04044859 is a phase 1 interventional trial sponsored by USWM CT, LLC. As of 21 Nov 2026, it is active and no longer recruiting. It studies Endometrial Cancer, Esophageal Cancer and 7 more conditions. The registry lists an enrollment of 120 participants at 17 sites in 3 countries. The registry lists a start date of 20 Aug 2019 and a primary completion date of 15 Apr 2026. One of its registered investigators has a FindMyKOL profile.

SponsorUSWM CT, LLCEnrollment120Endometrial CancerEsophageal CancerEsophagogastric Junction (EGJ)Gastric (Stomach) CancerHead and Neck CancerMelanoma+3 more conditions
View the registry record on ClinicalTrials.gov

Key facts

Registry attributes as recorded on the ClinicalTrials.gov study record.

Key facts for NCT04044859
FieldValue
Registry IDNCT04044859
StatusActive not recruiting
PhasePhase 1
Study typeInterventional trial
Lead sponsorUSWM CT, LLC
Enrollment120
Registered sites17
Countries3
ConditionsEndometrial Cancer, Esophageal Cancer, Esophagogastric Junction (EGJ), Gastric (Stomach) Cancer, Head and Neck Cancer, Melanoma and 3 more conditions
Start20 Aug 2019
Primary completion15 Apr 2026
Study completion30 Apr 2037
Last update posted23 Sept 2026

Registered summary

The lay summary the sponsor registered on ClinicalTrials.gov.

This study will investigate the safety and tolerability of ADP-A2M4CD8 T-cell therapy in subjects who have the appropriate human leukocyte antigen (HLA) and MAGE-A4 tumor antigen. Tumor indications include endometrial, esophageal, esophagogastric junction (EGJ), gastric, head and neck, melanoma, non-small cell lung (NSCLC), ovarian or urothelial cancer.

Investigators

The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

17 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

Florida, United States1 site
  • Name of Institution: Orlando Health Cancer Institute

    Orlando

Massachusetts, United States1 site
  • Massachusetts General Hospital

    Boston

Missouri, United States1 site
  • Washington University - School of Medicine

    St Louis

New York, United States1 site
  • Memorial Sloan Kettering Cancer Center

    New York

North Carolina, United States1 site
  • Duke University Medical Center, Duke Cancer Institute

    Durham

Oklahoma, United States1 site
  • Ou Health Stephenson Cancer Center

    Oklahoma City

Tennessee, United States1 site
  • Sarah Cannon Research Institute

    Nashville

Texas, United States1 site
  • M.D. Anderson Cancer Center

    Houston

Wisconsin, United States1 site
  • Froedtert Hospital and the Medical College of Wisconsin

    Milwaukee

Spain7 sites
  • Hospital Universitario 12 de Octubre

    Madrid, Avenida de Cordoba S/n

  • Clinica Universitaria de Navarra

    Pío, Pamplona

  • Hospital Clinico de Valencia

    Ibanez, Valencia

  • Hospital Universitario Vall D'Hebron

    Barcelona

  • Hospital Universitario Fundacion Jimenez Diaz

    Madrid

  • Hospital Universitario Hm Sanchinarro Ciocc

    Madrid

  • Hospital Universitario Virgen del Rocio

    Seville

Canada1 site
  • Princess Margaret Cancer Centre

    Toronto, Ontario

United States, by state

AlaskaAKMaineMEVermontVTNew HampshireNHWashingtonWAMontanaMTNorth DakotaNDMinnesotaMNWisconsin: 1 siteWI1MichiganMINew York: 1 siteNY1Massachusetts: 1 siteMA1Rhode IslandRIOregonORIdahoIDSouth DakotaSDIowaIAIllinoisILIndianaINOhioOHPennsylvaniaPANew JerseyNJConnecticutCTCaliforniaCANevadaNVWyomingWYNebraskaNEMissouri: 1 siteMO1KentuckyKYWest VirginiaWVVirginiaVAMarylandMDDelawareDEArizonaAZUtahUTColoradoCOKansasKSArkansasARTennessee: 1 siteTN1North Carolina: 1 siteNC1South CarolinaSCNew MexicoNMOklahoma: 1 siteOK1LouisianaLAMississippiMSAlabamaALGeorgiaGAHawaiiHITexas: 1 siteTX1Florida: 1 siteFL1District of ColumbiaDC
Fewer sitesMore sites

Outside the United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

No drug or biological interventions are in our data for this study. It may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →

Questions about NCT04044859

Each answer restates registry values shown on this page.

What is NCT04044859?

NCT04044859 is a phase 1 interventional trial sponsored by USWM CT, LLC. It studies Endometrial Cancer, Esophageal Cancer and 7 more conditions.

Is NCT04044859 recruiting?

As of 21 Nov 2026, it is active and no longer recruiting.

Who leads NCT04044859?

The registry names David Hong, MD (principal investigator, M.D. Anderson Cancer Center) as the overall official.

Where does NCT04044859 run?

The registry lists 17 sites in 3 countries. Most sites are in these countries: United States (9), Spain (7) and Canada (1).

When is NCT04044859 expected to complete?

The registry lists a primary completion date of 15 Apr 2026 and a study completion date of 30 Apr 2037. The sponsor last updated the record on 23 Sept 2026.

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 21 Nov 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.